Search

Your search keyword '"Balladelli, Alba"' showing total 34 results
Start Over Author "Balladelli, Alba"
34 results on '"Balladelli, Alba"'

15. Periosteal osteosarcoma

Author

Cesari, Marilena, primary, Alberghini, Marco, additional, Vanel, Daniel, additional, Palmerini, Emanuela, additional, Staals, Eric L., additional, Longhi, Alessandra, additional, Abate, Massimo, additional, Ferrari, Cristina, additional, Balladelli, Alba, additional, and Ferrari, Stefano, additional

Published
2010
Full Text
View/download PDF

16. Vincristine, Doxorubicin, Cyclophosfamide, Actinomycin D, Ifosfamide, and Etoposide in Adult and Pediatric Patients with Nonmetastatic Ewing Sarcoma. Final Results of a Monoinstitutional Study

Author

Ferrari, Stefano, primary, Palmerini, Emanuela, additional, Alberghini, Marco, additional, Staals, Eric, additional, Mercuri, Mario, additional, Barbieri, Enza, additional, Longhi, Alessandra, additional, Cantero, Laura, additional, Cesari, Marilena, additional, Abate, Massimo, additional, Balladelli, Alba, additional, Picci, Piero, additional, and Bacci, Gaetano, additional

Published
2010
Full Text
View/download PDF

23. Second Malignant Neoplasm in Patients With Osteosarcoma of the Extremities Treated With Adjuvant and Neoadjuvant Chemotherapy

Author

Bacci, Gaetano, primary, Ferrari, Cristina, additional, Longhi, Alessandra, additional, Ferrari, Stefano, additional, Forni, Cristiana, additional, Bacchini, Patrizia, additional, Palmerini, Emanuela, additional, Briccoli, Antonio, additional, Pignotti, Elettra, additional, Balladelli, Alba, additional, and Picci, Piero, additional

Published
2006
Full Text
View/download PDF

25. Analysis of 12q13-15 Genes in Parosteal Osteosarcoma

Author

Gamberi, Gabriella, primary, Ragazzini, Paola, additional, Benassi, Maria Serena, additional, Ferrari, Cristina, additional, Sollazzo, Maria Rosa, additional, Molendini, Lara, additional, Merli, Mara, additional, Magagnoli, Giovanna, additional, Ruggieri, Pietro, additional, Balladelli, Alba, additional, Orlando, Claudio, additional, Bacchini, Patrizia, additional, Pazzagli, Mario, additional, and Picci, Piero, additional

Published
2000
Full Text
View/download PDF

27. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma

Author

Benassi, M. Serena, primary, Molendini, Lara, additional, Gamberi, Gabriella, additional, Ragazzini, Paola, additional, Sollazzo, M. Rosa, additional, Merli, Mara, additional, Asp, Julia, additional, Magagnoli, Giovanna, additional, Balladelli, Alba, additional, Bertoni, Franco, additional, and Picci, Piero, additional

Published
1999
Full Text
View/download PDF

30. Periosteal osteosarcoma.

Author

Cesari, Marilena, Alberghini, Marco, Vanel, Daniel, Palmerini, Emanuela, Staals, Eric L., Longhi, Alessandra, Abate, Massimo, Ferrari, Cristina, Balladelli, Alba, and Ferrari, Stefano

Subjects
OSTEOSARCOMA, DRUG therapy, TUMOR surgery, HISTOLOGY, BONE cancer, THERAPEUTICS
Abstract

The article discusses research on the clinical and treatment factors that influence the survival of periosteal osteosarcoma patients. The study was conducted to thirty-three patients who received different regimen of treatments including surgery and chemotherapy according to grades of osteosarcoma. The results of the study revealed that the treatment of this disease needs a broad surgical removal of the tumor and that chemotherapy does not improve survival of the patient.

Published
2011
Full Text
View/download PDF

31. Imaging in bone sarcomas. The chemotherapist's point of view

Author

Alba Balladelli, Emanuela Palmerini, Stefano Ferrari, Daniel Vanel, Ferrari, Stefano, Balladelli, Alba, Palmerini, Emanuela, and Vanel, Daniel

Subjects
Diagnostic Imaging, medicine.medical_specialty, Radiology, Nuclear Medicine and Imaging, Staging, Adolescent, medicine.medical_treatment, Radiography, Computed tomography, Antineoplastic Agents, Bone Neoplasms, Bone Sarcoma, Tumor response, Bone sarcoma, medicine, Chemotherapy, Humans, Child, Reduction (orthopedic surgery), Neoplasm Staging, Osteosarcoma, medicine.diagnostic_test, business.industry, Tumor imaging, Follow-up, Tumor shrinkage, Magnetic resonance imaging, General Medicine, medicine.disease, Prognosis, Treatment Outcome, Child, Preschool, Radiology, business, Calcification
Abstract

The role of imaging in planning oncologic treatment and follow-up of patients with bone sarcomas is dis-cussed in the present article. Tumor staging and radiographic assessment of response to chemotherapy inbone sarcomas may be of difficult interpretation. In particular, the use of the criterion of tumor shrinkageto measure response to chemotherapy is not always applicable in bone tumors where higher calcificationrather than reduction in size is frequently observed. New techniques such as (18)F-FDG PET/CT, dynamiccontrast-enhanced computed tomography or magnetic resonance are now available allowing a moreaccurate staging of patients and adding information for the evaluation of tumor response. Innovativeapproaches aiming to evaluate vascular and metabolic response rather than mono- or bi-dimensionalchanges may be more informative and require further investigations. © 2011 Elsevier Ireland Ltd. All rights reserved.

Published
2012

32. Periosteal osteosarcoma: a single-institution experience

Author

Stefano Ferrari, Marilena Cesari, Marco Alberghini, Daniel Vanel, Emanuela Palmerini, Alessandra Longhi, Eric L. Staals, Alba Balladelli, Cristina Ferrari, Massimo Eraldo Abate, Cesari, Marilena, Alberghini, Marco, Vanel, Daniel, Palmerini, Emanuela, Staals, Eric L., Longhi, Alessandra, Abate, Massimo, Ferrari, Cristina, Balladelli, Alba, and Ferrari, Stefano

Subjects
Adult, Male, Cancer Research, medicine.medical_specialty, Adolescent, periosteal osteosarcoma, medicine.medical_treatment, Bone Neoplasms, Disease, chemotherapy, surgery, Recurrence, Periosteum, rare tumor, medicine, Humans, Single institution, Neoplasm Metastasis, Child, Survival rate, Retrospective Studies, Chemotherapy, Osteosarcoma, business.industry, Cancer, Retrospective cohort study, medicine.disease, Surgery, Radiation therapy, Oncology, Female, business
Abstract

BACKGROUND: Periosteal osteosarcoma is a rare variant of osteosarcoma. Wide surgical removal is the mainstay of treatment, but controversy remains about the role of chemotherapy. The objective of this study was to review and analyze the clinical and treatment-related factors that influence the survival of patients with periosteal osteosarcoma who received treatment in a single institution. METHODS: Thirty-three patients with periosteal osteosarcoma (19 males and 14 females) with a median age of 16 years (range, ages 6-32 years) underwent surgery (32 patients) and received radiotherapy (1 patient). Chemotherapy was received according to different regimens for high-grade osteosarcoma by 14 patients who had grade 3 tumors. RESULTS: The 10-year overall survival rate was 84%. The only patient who did not undergo surgery died of disease after 9 months; for the remaining 32 patients the 10-year disease-free survival rate was 65%. Survival was not influenced by the receipt of chemotherapy. The patients who received chemotherapy had a 10-year overall survival rate of 86%, and those who received only local treatment had an overall survival rate of 83% (P ¼ .73). CONCLUSIONS: The authors’ experience indicated that the treatment of periosteal osteosarcoma requires only wide surgical removal of the tumor and that adjuvant chemotherapy does not improve survival. Cancer 2010;000:000–000. V C 2010 American Cancer Society.

Published
2010

33. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age.

Author

Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E, Abate ME, Marchesi E, Balladelli A, Pratelli L, and Ferrari S

Subjects
Adolescent, Adult, Age Factors, Bone Neoplasms pathology, Child, Child, Preschool, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Etoposide administration & dosage, Female, Follow-Up Studies, Humans, Ifosfamide administration & dosage, Male, Melphalan administration & dosage, Mesna administration & dosage, Neoplasm Staging, Prognosis, Prospective Studies, Sarcoma, Ewing pathology, Sex Factors, Survival Rate, Vincristine administration & dosage, Young Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bone Neoplasms drug therapy, Hematologic Diseases chemically induced, Sarcoma, Ewing drug therapy
Abstract

Influence of age and sex on chemotherapy-related toxicity was evaluated in children (3-9 years), adolescents (10-17 years), and adults (up to 40 years) with localized Ewing sarcoma (ES) enrolled in the ISG/SSG III protocol. Treatment was based on vincristine, doxorubicin, cyclophosphamide, ifosfamide, dactinomycin, and etoposide. High-dose chemotherapy with busulfan and melphalan was given in poor responder patients. The analysis was based on 2191 courses of standard chemotherapy and 230 patients. A lower risk of G4 leukopenia and thrombocytopenia, hospitalization, febrile neutropenia, and red blood cell (RBC) transfusions was observed in males. Use of granulocyte colony-stimulating factor (G-CSF) was more frequent in adults, while children more often received RBC transfusions. A significant correlation between sex and chemotherapy-related toxicity was observed in the study, whereas no significant differences in terms of bone marrow toxicity can be expected according to patient age. Further studies should analyse the role of pharmacokinetics, pharmacogenomics, and clinical characteristics.

Published
2014
Full Text
View/download PDF

34. Activation of metalloproteinases-2 and -9 by interleukin-1alpha in S100A4-positive liposarcoma cell line: correlation with cell invasiveness.

Author

Pazzaglia L, Ponticelli F, Magagnoli G, Magagnoli G, Gamberi G, Ragazzini P, Balladelli A, Picci P, and Benassi M

Subjects
Cell Line, Tumor, Enzyme Activation, Flow Cytometry, Humans, Immunohistochemistry, Interleukin-6 pharmacology, Liposarcoma enzymology, Liposarcoma genetics, Liposarcoma pathology, Neoplasm Invasiveness, S100 Calcium-Binding Protein A4, S100 Proteins genetics, Tissue Inhibitor of Metalloproteinase-1 biosynthesis, Tissue Inhibitor of Metalloproteinase-1 genetics, Tissue Inhibitor of Metalloproteinase-2 biosynthesis, Tissue Inhibitor of Metalloproteinase-2 genetics, Interleukin-1 pharmacology, Liposarcoma metabolism, Matrix Metalloproteinase 2 metabolism, Matrix Metalloproteinase 9 metabolism, S100 Proteins biosynthesis
Abstract

Background: The S100A4 gene may affect the invasive properties of tumor cells through modulation of metalloproteinases (MMPs) and their inhibitors (TIMPs)., Materials and Methods: In the human liposarcoma cell line, SW872, we analyzed the expression of S100A4 protein by immunohistochemistry and flow cytometry. The production of MMP2, MMP9, TIMP1 and TIMP2 was assessed by gelatin zymography and enzyme-linked immunoabsorbent assay before and after interleukin-1alpha (IL-1alpha) and interleukin-6 (IL-6) stimulation; cell invasiveness was measured by Matrigel invasion assay., Results: S100A4-positive SW872 cells responded to IL-1alpha with induction of immunoreactive MMP2 and TIMP1 and with activation of both MMPs, the latter significantly associated with an increase of cell invasiveness. Treatment with IL-6 induced less significant variations resulting in a more stable invasive behavior., Conclusion: These data show that S100A4-positive SW872 respond to interleukins by influencing the behavior of factors involved in extracellular matrix degradation and emphasize the predominant role of MMP activity status on the positive regulation of cell migration mechanisms.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results